Severe post-COVID-19 costochondritis in children

Collins, Reagan A.; Ray, Nandini; Ratheal, Kelly; Colon, Athos

doi:10.1080/08998280.2021.1973274

Cited by 9 publications

(13 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Twenty literature reviews were identified2, 12-30 . Of the remaining studies, 31 presented original research 31-61 , 6 were case series 62-67 , 24 were case reports 68-91 , 1 provided a specialist’s opinion 92 , 4 were editorials 93-96 , and 2 were letters to the editor 97,98 .…”

Section: Resultsmentioning

confidence: 99%

What Do We Need to Know About Musculoskeletal Manifestations of COVID-19?

et al. 2022

View full text Add to dashboard Cite

COVID-19 is a disease that is challenging science, health-care systems, and humanity. An astonishingly wide spectrum of manifestations of multiorgan damage, including musculoskeletal, can be associated with SARS-CoV-2. » In the acute phase of COVID-19, fatigue, myalgia, and arthralgia are the most common musculoskeletal symptoms.» Post-COVID-19 syndrome is a group of signs and symptoms that are present for .12 weeks. The associated musculoskeletal manifestations are fatigue, arthralgia, myalgia, new-onset back pain, muscle weakness, and poor physical performance.» Data on COVID-19 complications are growing due to large absolute numbers of cases and survivors in these 2 years of the pandemic. Additional musculoskeletal manifestations encountered are falls by the elderly, increased mortality after hip fracture, reduced bone mineral density and osteoporosis, acute sarcopenia, rhabdomyolysis, Guillain-Barr é syndrome, muscle denervation atrophy, fibromyalgia, rheumatological disease triggering, septic arthritis, adhesive capsulitis, myositis, critical illness myopathy, onset of latent muscular dystrophy, osteonecrosis, soft-tissue abscess, urticarial vasculitis with musculoskeletal manifestations, and necrotizing autoimmune myositis.

show abstract

Section: Resultsmentioning

confidence: 99%

What Do We Need to Know About Musculoskeletal Manifestations of COVID-19?

et al. 2022

View full text Add to dashboard Cite

show abstract

“…Included studies came from 47 different countries although the majority were from Europe (43) 24, 28-32,34,36,39,40,44,49,50,52,53,55,58-60,68,74,75,77-79,81,82,84,88-91,94-96,98,103,104,107,113,114, and the USA (26) 33,35,37,[41][42][43][45][46][47][48]57,61,63,67,[69][70][71]76,83,86,93,99,[109][110][111][112] . Articles were translated from Norwegian, Russian, and Mandarin.…”

Section: Resultsmentioning

confidence: 99%

“…Articles were translated from Norwegian, Russian, and Mandarin. 38 were case reports 23,33,36,41,43,47,48,51,52,55,57,[60][61][62]64,[66][67][68][69][70]72,78,80,[85][86][87]89,92,[98][99][100][101]107,108,110,112 . Of those that were not case reports, most were cohort studies (26) 23,24,33,36,41,43,47,48,51,52,55,57,[60][61][62][64]…”

Section: Resultsmentioning

confidence: 99%

Long-term outcomes of COVID-19 infection in children and young people: a systematic review and meta-analysis

Twohig

Bajpai

Corp

et al. 2023

Preprint

View full text Add to dashboard Cite

Background Children and young people (CYP) may experience prolonged symptoms following COVID-19, commonly termed "Long-COVID". The nature of this in CYP is unclear, as are the sequalae of acute COVID-19. We aimed to systematically synthesise evidence of the long-term outcomes of COVID-19 in CYP. Methods 13 databases were searched until January 2022. Inclusion criteria: Observational studies reporting outcomes occurring four-weeks or more after COVID-19 in children <18 years old. Exclusion criteria: Outcomes of Paediatric Inflammatory Multisystem Syndrome. Title, abstract and full text screening were conducted independently by two reviewers. Data extraction and risk of bias assessment was by one reviewer with independent verification. Critical appraisal tools appropriate for study type were employed. Results were narratively synthesised with meta-analysis to generate summary estimates of risk of prolonged symptoms in CYP. Findings 94 studies were included. 66 recruited from hospital settings, 8 recruited solely from community settings. >100 symptoms were reported, the most common being fatigue, headache and cognitive symptoms. Summary estimates of risk of prolonged symptoms were higher for hospital samples (31.2%, 95% CI 20.3% to 43.2%) than for community samples (4.6%, 95% CI 3.4% to 5.8). Sequalae including stroke, type-1 diabetes, Guillan-Barre syndrome, and persistent radiological or blood test abnormalities have been reported in CYP following COVID-19. Most studies reporting these are case reports / case series and quality of evidence is low. Interpretation Prolonged symptoms following COVID-19 in children are variable and multi-system. Rates in community samples are lower than hospital. There is limited data on other sequalae in CYP. Heterogeneity in diagnosis of COVID-19, symptom classification, assessment method and duration of follow-up made synthesis less secure. Funding HT, CB and GS have National Institute for Health and Care Research fellowships. RB, CM and VW are supported by the NIHR West Midlands Applied Research Collaboration. CM Is supported by the NIHR School for Primary Care Research Research in context panel Evidence before this study At the time of writing and to the best of our knowledge, the protocol for this systematic review was a novel endeavour to summarise the longer-term effects of COVID-19 in children and young people (CYP). At least three systematic reviews have since been published, summarising the symptom profile and prevalence of Long-COVID in CYP, but prevalence estimates vary widely and the evidence base remains uncertain. In addition, there is very limited information on other sequalae of COVID-19 in this population group. We searched thirteen electronic databases (MEDLINE, EMBASE, AMED, HMIC, CINAHLPlus, PsycINFO, Web of Science (Science Citation and Social Science Citation indicies), ASSIA, WHO COVID-19: Global literature on coronavirus disease, Cochrane COVID-19 study register, ProQuest Coronavirus research database, NDLTD and OpenGrey) up to January 2022 for any empirical study including search terms pertaining to longer term symptoms of COVID-19 in CYP (<18 years old). The quality of the studies was mixed. Results were analysed narratively for each objective, and random effects meta-analyses conducted to estimate risk of prolonged symptoms in CYP who have had COVID-19. Added value of this study This review adds to the evidence of the heterogeneity of prolonged symptoms following COVID-19 in CYP but importantly, stratifies risk of this by recruitment setting. We also synthesise evidence on broader sequalae of the acute infection in this CYP and longer-term effects in CYP with pre-existing conditions, which have not been considered in previous reviews. We purposefully included case studies and case series, to capture emerging patterns of outcomes, which may well be important in a novel condition with a rapidly increasing volume of publications. To our knowledge, this systematic review and meta-analysis is the most comprehensive to date. Implications of all the available evidence This review adds to the evidence that a substantial proportion of CYP do experience effects of COVID-19 that last longer than four-weeks, with the most frequently reported prolonged symptoms being fatigue, headache and cognitive symptoms. The proportion of CYP developing prolonged symptoms in children recruited from community setting was low, although this may translate to a large number of affected CYP at population level. There is a paucity of controlled studies and this limits confidence that prolonged symptoms are attributable to COVID-19. Sequalae including stroke, type-1 diabetes, Guillan-Barre syndrome, and persistent radiological or blood test abnormalities have been reported in CYP following COVID-19 but most studies reporting these are case reports / case series and quality of evidence is low. To develop treatment plans and interventions for affected CYP, further studies are needed to better characterise this condition and understand its impact on the lives of CYP and their families and communities. These should ideally recruit from community settings, include population-based control groups and consider using standardised definitions and outcome measures where possible.

show abstract

“…This condition might resolve spontaneously or require a short treatment with nonsteroidal anti-inflammatory drugs such as ibuprofen. The Costochondritis symptoms due to COVID-19 infection are more severe than COVID-19 vaccine-related costochondritis [ 25 , 26 ].…”

Section: Resultsmentioning

confidence: 99%

Uncommon Side Effects of COVID-19 Vaccination in the Pediatric Population

Pandit¹,

Pandit²,

Goyal³

2022

Cureus

View full text Add to dashboard Cite

Introduction The rapid development of vaccines followed the Coronavirus disease 2019 (COVID-19) pandemic. There is still significant vaccine hesitancy, especially among parents. Large-scale pediatric population-based studies or reviews about vaccine side effects are limited. Data sources and methods The Centers for Disease Control and Prevention (CDC) recommends recipients or their providers notify possible adverse events to the Vaccine Adverse Event Reporting System (VAERS). We evaluated Delaware state data from the VAERS system for the pediatric age group. Results A total of 111 reports were reviewed, with summaries of the reported key side effects discussed, including seizures, myocarditis, stroke, multisystem inflammatory syndrome in children (MIS-C), chest pain, hematuria, menstrual disorder, appendicitis, behavioral and otological side effects, etc. Conclusions We noted the approximate prevalence of reported adverse events to be <0.2%. Further studies with larger sample sizes or those focused on each key side effect are needed to evaluate these side effects in detail. An open discussion about the possible side effects and reinforcing the individual, family, and community benefits are key to promoting COVID-19 vaccine acceptance.

show abstract

Severe post-COVID-19 costochondritis in children

Cited by 9 publications

References 11 publications

What Do We Need to Know About Musculoskeletal Manifestations of COVID-19?

What Do We Need to Know About Musculoskeletal Manifestations of COVID-19?

Long-term outcomes of COVID-19 infection in children and young people: a systematic review and meta-analysis

Uncommon Side Effects of COVID-19 Vaccination in the Pediatric Population

Contact Info

Product

Resources

About